These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35238838)

  • 21. Rare germline genetic variants and risk of aggressive prostate cancer.
    Nguyen-Dumont T; MacInnis RJ; Steen JA; Theys D; Tsimiklis H; Hammet F; Mahmoodi M; Pope BJ; Park DJ; Mahmood K; Severi G; Bolton D; Milne RL; Giles GG; Southey MC
    Int J Cancer; 2020 Oct; 147(8):2142-2149. PubMed ID: 32338768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening.
    Byrne L; Toland AE
    Urol Clin North Am; 2021 Aug; 48(3):387-399. PubMed ID: 34210493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate Cancer Predisposition.
    Bhanji Y; Isaacs WB; Xu J; Cooney KA
    Urol Clin North Am; 2021 Aug; 48(3):283-296. PubMed ID: 34210485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for familial and hereditary prostate cancer.
    Lynch HT; Kosoko-Lasaki O; Leslie SW; Rendell M; Shaw T; Snyder C; D'Amico AV; Buxbaum S; Isaacs WB; Loeb S; Moul JW; Powell I
    Int J Cancer; 2016 Jun; 138(11):2579-91. PubMed ID: 26638190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
    Oliva L; Lozano R; Llácer C; Aragón I; Pajares BI; Sáez MI; Herrera-Imbroda B; Montesa A; Hernández D; Villatoro R; Otero A; Correa R; Grau G; Peinado P; Pacheco MI; García-Galisteo E; Rueda A; Machuca FJ; Alba E; Márquez-Aragonés A; Olmos D; Castro E
    Eur Urol Oncol; 2021 Apr; 4(2):315-318. PubMed ID: 31307957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.
    Agalliu I; Karlins E; Kwon EM; Iwasaki LM; Diamond A; Ostrander EA; Stanford JL
    Br J Cancer; 2007 Sep; 97(6):826-31. PubMed ID: 17700570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerations of germline testing in prostate cancer screening.
    Polascik TJ; Orabi H
    Can J Urol; 2019 Oct; 26(5 Suppl 2):46-47. PubMed ID: 31629431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reimagining prostate cancer screening: the IMPACT of germline mutations.
    Gandaglia G; Briganti A; Montorsi F
    Lancet Oncol; 2021 Nov; 22(11):1491-1492. PubMed ID: 34678157
    [No Abstract]   [Full Text] [Related]  

  • 29. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance.
    Helfand BT; Xu J
    Urol Clin North Am; 2021 Aug; 48(3):401-409. PubMed ID: 34210494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
    Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
    J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    Siebert AL; Szymaniak BM; Numan Y; Morgans AK
    Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
    Harper JB; Greenberg SE; Hunt TC; Cooney KA; O'Neil BB
    Prostate; 2023 Feb; 83(2):151-157. PubMed ID: 36207779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression.
    Xu J; Shi Z; Wei J; Na R; Resurreccion WK; Wang CH; Sample C; Han M; Zheng SL; Cooney KA; Helfand BT; Isaacs WB
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):749-754. PubMed ID: 35149774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline Predisposition to Prostate Cancer in Diverse Populations.
    Bree KK; Hensley PJ; Pettaway CA
    Urol Clin North Am; 2021 Aug; 48(3):411-423. PubMed ID: 34210495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline mutations and prostate cancer: is it time to change treatment algorithms?
    Telvizian T; Mukherji D
    Chin Clin Oncol; 2020 Oct; 9(5):65. PubMed ID: 32921062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
    Brady L; Newcomb LF; Zhu K; Zheng Y; Boyer H; Sarkar N; McKenney JK; Brooks JD; Carroll PR; Dash A; Ellis WJ; Filson CP; Gleave ME; Liss MA; Martin F; Morgan TM; Thompson IM; Wagner AA; Pritchard CC; Lin DW; Nelson PS
    Cancer Med; 2022 Nov; 11(22):4332-4340. PubMed ID: 35467778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.